ライフサイエンスコーパス: lipid nanoparticle

1 YC mice, which develop hepatoblastoma, using lipid nanoparticles.

2 ived from the leukocyte plasma membrane into lipid nanoparticles.

3 livery to the lungs using degradable polymer-lipid nanoparticles.

4 dy VRC01 are generated and encapsulated into lipid nanoparticles.

5 rmation of oxidatively and physically stable lipid nanoparticles.

6 SSOs were delivered in vivo using lipid nanoparticles.

7 overed that 4-(N)-stearoyl gemcitabine solid lipid nanoparticles (4-(N)-GemC18-SLNs) can overcome mul

8 Here we present an optimized lipid nanoparticle and a CCR2-silencing short interferin

9 hepatitis C virus (HCV) were formulated into lipid nanoparticles and administered intravenously to HC

10 two well-established siRNA delivery systems, lipid nanoparticles and cholesterol conjugated-siRNAs.

11 classes of siRNA delivery systems, including lipid nanoparticles and siRNA conjugates, are designed t

12 e components, as seen in stable nucleic-acid-lipid nanoparticles and the cyclodextrin polymer, will b

13 lease of siRNAs, formulated in lipoplexes or lipid nanoparticles, by live-cell imaging and correlated

14 d 4-(N)-stearoyl cytarabine carried by solid lipid nanoparticles can also overcome the resistance.

15 erfering RNA (siRNA) has been realized using lipid nanoparticles, cationic complexes, inorganic nanop

16 tained by developing a novel system based on lipid nanoparticles conjugated with an anti-CD38 monoclo

17 mates and highlight the rapid development of lipid-nanoparticle-delivered siRNA as a countermeasure a

18 We tested in mice two vaccine platforms, a lipid nanoparticle-encapsulated modified mRNA vaccine en

19 ingle low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA

20 Here we show that lipid-nanoparticle-encapsulated short interfering RNAs (

21 d over 25 days after a single treatment of a lipid nanoparticle-formulated siRNA targeting luciferase

22 Using lipid nanoparticle formulations of these enhanced sgRNAs

23 Lipid nanoparticles functionalized with targeting peptid

24 first- and second-generation formulations of lipid nanoparticles, generating ALN-TTR01 and ALN-TTR02,

25 id pK(a) in the in vivo delivery of siRNA by lipid nanoparticles has been studied with a large number

26 Lipid nanoparticles have been used for carrying differen

27 order the effectiveness of siRNA delivery by lipid nanoparticles in vivo.

28 Lactosylated gramicidin-containing lipid nanoparticles (Lac-GLN) were developed for deliver

29 ronmental contaminants via permeation across lipid nanoparticles (liposomes) as a mimicry of biologic

30 The development of lipid nanoparticle (LNP) based small interfering RNA (si

31 ere, we assessed the therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprot

32 We engineered a lipid nanoparticle (LNP) encapsulated modified mRNA vacc

33 n, synthesis, and biological evaluation of a lipid nanoparticle (LNP) system that can encapsulate mRN

34 targeting the SUDV VP35 gene encapsulated in lipid nanoparticle (LNP) technology with increased poten

35 oro-modified derivative (dsP21-322-2'F) into lipid nanoparticles (LNP) for intravesical delivery.

36 nistered K-Ras-beta-catenin mice with EnCore lipid nanoparticles (LNP) loaded with a Dicer substrate

37 Lipid nanoparticles (LNPs) are efficient carriers for sh

38 ies of alkenyl amino alcohol (AAA) ionizable lipid nanoparticles (LNPs) capable of delivering human m

39 then we developed CH6 aptamer-functionalized lipid nanoparticles (LNPs) encapsulating osteogenic plec

40 preparation of high-quality siRNA-containing lipid nanoparticles (LNPs) for a large number of materia

41 ct lead candidates for in vivo evaluation of lipid nanoparticles (LNPs) for systemic small interferin

42 Hbb(th3/+)) with Tmprss6 siRNA formulated in lipid nanoparticles (LNPs) that are preferentially taken

43 ltiparametric approach for the evaluation of lipid nanoparticles (LNPs) to identify relationships bet

44 mic, in vivo, nonviral mRNA delivery through lipid nanoparticles (LNPs) to treat a Factor IX (FIX)-de

45 f short interfering RNA (siRNA) delivered in lipid nanoparticles (LNPs) using cellular trafficking pr

46 Next, FXN mRNA, in the form of lipid nanoparticles (LNPs), was administered intravenous

47 ivery of short interfering RNA (siRNA) using lipid nanoparticles (LNPs), we developed a self-amplifyi

48 (DEN-80E) formulated with ionizable cationic lipid nanoparticles (LNPs).

49 After intravenous injection, up to 90% of lipid nanoparticles loaded with small interfering RNA to

50 vanced liver fibrosis that received cationic lipid nanoparticles loaded with small interfering RNA to

51 Our lipid nanoparticles loaded with small interfering RNA to

52 rgos: a protein, bovine serum albumin, and a lipid nanoparticle, low-density lipoprotein.

53 derivatives of nucleoside analogs into solid lipid nanoparticles may represent a platform technology

54 Here, we combine lipid nanoparticle-mediated delivery of Cas9 mRNA with a

55 y systems include micelles, liposomes, solid lipid nanoparticles, nanoemulsions and nanosuspensions.

56 Here, we encapsulated cdGMP within PEGylated lipid nanoparticles (NP-cdGMP) to redirect this adjuvant

57 TKM-130803, a small interfering RNA lipid nanoparticle product, has been developed for the t

58 NP-718m siRNA in lipid nanoparticles provided 100% protection against MAR

59 straints for practical applications of solid lipid nanoparticles (SLN) as oral delivery vehicles.

60 and omega-3 fish oil, (ii) tristearin solid lipid nanoparticles (SLN), and (iii) omega-3 fish oil-in

61 oil--on the structural arrangement of solid lipid nanoparticles (SLN).

62 ypothesized that CPA solubilized in a liquid-lipid nanoparticle system (CPA-LLP) for intravenous inje

63 Further development of the lipid nanoparticle technology has the potential to yield

64 describe an approach for engineering peptide-lipid nanoparticles that function similarly to high-dens

65 sphatidylcholine, as a minimalist model of a lipid nanoparticle, to evaluate both the interaction ene

66 MPER-derived peptides were incorporated into lipid nanoparticles using natural and designed TM domain

67 A lipid nanoparticle was developed that allowed nuclear ta

68 e of hepatitis C virus (HCV) formulated with lipid nanoparticles, was able to suppress viral replicat

69 Gadolinium lipid nanoparticles were able to identify tumor-induced

70 The multivalent peptide-lipid nanoparticles were also remarkably stable toward e

71 conditions (e.g., pH and temperature), solid lipid nanoparticles were prepared by the dilution of wat

72 different doxorubicin and paclitaxel-loaded lipid nanoparticles were prepared.

73 Here we report that combining bioreducible lipid nanoparticles with negatively supercharged Cre rec